8-K: Adagio Medical Sets 2025 Annual Meeting Date
Annual Meeting Announcement
Adagio Medical Holdings, Inc. announced the date for its 2025 Annual Meeting of Stockholders and critical deadlines for shareholder proposals and director nominations.
Summary
- The Board of Directors of Adagio Medical Holdings, Inc. established December 15, 2025, as the date for the 2025 Annual Meeting of Stockholders.
- The record date for stockholders entitled to notice and vote at the 2025 Annual Meeting is the close of business on October 31, 2025.
- The company is filing this 8-K because it did not hold a 2024 Annual Meeting of Stockholders.
- Stockholder proposals for inclusion in proxy materials under Rule 14a-8 must be received by November 3, 2025.
- Stockholder director nominations or other proposals under the company's bylaws must be received by November 3, 2025.
- Stockholders intending to solicit proxies for director nominees other than the company's nominees must provide notice under Rule 14a-19 by November 3, 2025.
Sentiment
Score: 5
Explanation: The filing is purely administrative, announcing the date for the annual meeting and related deadlines, with no financial or operational updates.
Negatives
- The company did not hold a 2024 Annual Meeting of Stockholders, which is an unusual administrative lapse.
Future Outlook
The time and location of the 2025 Annual Meeting will be set forth in the company's definitive proxy statement, which will be filed with the SEC.
Industry Context
This filing is an administrative announcement regarding an upcoming annual shareholder meeting, a standard corporate governance requirement. The absence of a 2024 annual meeting is an unusual administrative event for a publicly traded company.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Annual Meeting Scheduling | Establishment of the 2025 Annual Meeting date and associated deadlines for shareholder proposals and director nominations. | 2025-10-23 | Ensures compliance with SEC regulations for shareholder engagement and corporate governance, addressing the lapse of a 2024 meeting. |
| Bylaw Compliance | Clarification of requirements for stockholder director nominations and other proposals as per the company's amended and restated bylaws. | 2025-10-23 | Provides clear guidelines for shareholders to participate in the nomination and proposal process, maintaining corporate governance standards. |
| SEC Rule Compliance | Adherence to Rule 14a-8 for shareholder proposals and Rule 14a-19 (universal proxy rules) for director nominees. | 2025-10-23 | Ensures the company's proxy solicitation process aligns with current SEC regulations, facilitating transparent shareholder participation. |
Stakeholder Impact
- Shareholders: Provided with key dates for the 2025 Annual Meeting, including the record date and deadlines for submitting proposals and director nominations, enabling their participation in corporate governance.
Next Steps
- The company will file its definitive proxy statement for the 2025 Annual Meeting with the SEC.
- The 2025 Annual Meeting of Stockholders will be held on December 15, 2025.
Key Dates
| Date | Description |
|---|---|
| 2025-10-23 | Date of earliest event reported; Board of Directors established the 2025 Annual Meeting date. |
| 2025-10-24 | Date the Current Report on Form 8-K was signed. |
| 2025-10-31 | Record date for determining stockholders entitled to notice of, and to vote at, the 2025 Annual Meeting. |
| 2025-11-03 | Deadline for submission of stockholder proposals under Rule 14a-8, stockholder director nominations, and Rule 14a-19 notices. |
| 2025-12-15 | Date of the 2025 Annual Meeting of Stockholders. |
Recommendation
holdThis filing is purely administrative, announcing the date for the 2025 Annual Meeting and associated deadlines. It contains no new financial, operational, or strategic information that would warrant a change in investment recommendation. Investors should await the definitive proxy statement and any subsequent financial reports for substantive updates.
Keywords
Adagio Medical Holdings, ADGM, 8-K, Annual Meeting, Shareholder Nominations, Proxy Statement, Corporate Governance, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.